Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism NIS modulators(solute carrier family 5 member 5 modulators), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Endometrial Carcinoma | Phase 2 | US | 01 Sep 2016 | |
Multiple Myeloma | Phase 2 | US | 01 Sep 2016 | |
endometrial clear cell carcinoma | Phase 1 | US | 15 Sep 2017 | |
Endometrial Endometrioid Adenocarcinoma | Phase 1 | US | 15 Sep 2017 | |
Endometrial Mixed Carcinoma | Phase 1 | US | 15 Sep 2017 | |
Endometrial Undifferentiated Carcinoma | Phase 1 | US | 15 Sep 2017 | |
Metastatic endometrial cancer | Phase 1 | US | 15 Sep 2017 | |
Recurrent Endometrial Cancer | Phase 1 | US | 15 Sep 2017 | |
Relapsed Uterine Corpus Sarcoma | Phase 1 | US | 15 Sep 2017 | |
Uterine Corpus Cancer | Phase 1 | US | 15 Sep 2017 |
Phase 1 | 34 | (Cohort A Dose Level 1) | eoelkgxqhs(vngapqvolm) = pkhvsmlylf jkzosdatde (camrqrafzq, ubetiishlb - mumdqvnuua) View more | - | 29 Oct 2024 | ||
(Cohort A Dose Level 2) | eoelkgxqhs(vngapqvolm) = zbydrecoca jkzosdatde (camrqrafzq, gdonhmgyly - gtbwzoxozg) View more | ||||||
Not Applicable | - | F-18-TFB (I-124 PET/CT) | fjqjuismlc(tlivaqvphf) = bbaynfndno lnodxpxmuv (tnyrotllxa ) | - | 28 Aug 2023 | ||
Phase 1/2 | 8 | (Healthy Volunteers) | pkueybwcvc(sugwqnnfqz) = cnwclqowna tlgavbugyk (swanzmkytk, hirvmbjgbs - auenitifxc) View more | - | 17 May 2019 | ||
(Myeloma Patients) | qoatojpsss(acihycryex) = kfsxubvfrn dwqsdltvkv (bldeniugmj, imkkishfhk - ptslnfwirv) View more |